Method for improving the stability of purified factor VIII after reconstitution
The present invention relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing of the Factor VIII molecule. The invention further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.
1. A method for improving the bioavailability of a Factor VIII molecule after non-intravenous administration, comprising non-intravenously administering a modified Factor VIII molecule to a subject at a reduced dosage,
wherein the modified Factor VIII molecule comprises a Factor VIII molecule modified by inactivating the proteolytic cleavage site between Arg1648 and Glu1649, and, if present in the Factor VIII molecule, the proteolytic cleavage site between Arg1313 and Ala1314, and
wherein the modified Factor VIII molecule is non-intravenously administered at a dosage of 20 IU/kg to 50 IU/kg, while at least maintaining or improving the bioavailability as compared to (A) a higher dosage of a non-intravenously administered human wild type Factor VIII molecule, and/or (B) a higher dosage of a non-intravenously administered B-domain deleted human Factor VIII molecule in which Asn745 is fused to Pro1640,
and wherein the non-intravenous administration is chosen from subcutaneous, intramuscular, intraperitoneal, intradermal, and transdermal administration.
2. The method of claim 1 , wherein the non-intravenous administration is subcutaneous, transdermal or intramuscular injection.
3. A method for improving the plasma half-life of a Factor VIII molecule, comprising non-intravenously administering a modified Factor VIII molecule to a subject at a reduced dosage,
wherein the modified Factor VIII molecule comprises a Factor VIII molecule modified by inactivating the proteolytic cleavage site between Arg1648 and Glu1649, and, if present in the Factor VIII molecule, the proteolytic cleavage site between Arg1313 and Ala1314, and
wherein the modified Factor VIII molecule is administered at a dosage of 20 IU/kg to 50 IU/kg, while at least maintaining or improving the plasma half-life as compared to a higher dosage of a non-intravenously administered human wild type Factor VIII molecule,
and wherein the non-intravenous administration is chosen from subcutaneous, intramuscular, intraperitoneal, intradermal, and transdermal administration.
4. The method of any one of claims 1 to 3 , wherein the modified Factor VIII comprises SEQ ID NO: 2 modified to have a first amino acid selected from the amino acids at positions 741 to 1647 of SEQ ID NO: 2 fused to a second amino acid selected from the amino acids at positions 1649 to 1690 of SEQ ID NO: 2, deleting the intervening amino acids, whereby the proteolytic cleavage site between Arg1648 and Glu1649, and, if present in the modified Factor VIII molecule, the proteolytic cleavage site between Arg1313 and Ala1314, is inactivated.
5. A method of treatment or prophylaxis for a bleeding disorder, comprising non-intravenously administering a modified Factor VIII molecule to a subject,
wherein the modified Factor VIII molecule comprises a Factor VIII molecule modified by inactivating the proteolytic cleavage site between Arg1648 and Glu1649, and, if present in the Factor VIII molecule, the proteolytic cleavage site between Arg1313 and Ala1314, and
wherein the modified Factor VIII molecule is administered at a dosage of 20 IU/kg to 50 IU/kg,
and wherein the non-intravenous administration is chosen from subcutaneous, intramuscular, intraperitoneal, intradermal, and transdermal administration.
6. The method of claim 5 , wherein the non-intravenous administration is subcutaneous, transdermal or intramuscular injection.
7. The method of claim 5 , wherein the modified Factor VIII comprises SEQ ID NO: 2 modified to have a first amino acid selected from the amino acids at positions 741 to 1647 of SEQ ID NO: 2 fused to a second amino acid selected from the amino acids at positions 1649 to 1690 of SEQ ID NO: 2, deleting the intervening amino acids, whereby the proteolytic cleavage site between Arg1648 and Glu1649, and, if present in the modified Factor VIII molecule, the proteolytic cleavage site between Arg1313 and Ala1314, is inactivated.